- In October 2024, Mölnlycke Health Care partnered with Transdiagen (TDG), a precision medicine company, to research chronic wound healing and tissue regeneration using TDG’s novel wound gene signatures. This collaboration will help Mölnlycke enhance its wound care products by integrating advanced genetic insights for more effective treatment
- In October 2024, Swift Medical launched its "Skin & Wound 2" platform, featuring advanced interoperability standards, imaging, and documentation tools. With over 50 million patient assessments across various healthcare settings, this platform will enhance the company’s ability to provide efficient, data-driven wound care solutions and improve patient outcomes
- In October 2024, Sonoma Pharmaceuticals amended its distribution agreement with a major global healthcare distributor to market and distribute its Microcyn-based wound care products in Canada. This expansion will help the company increase its market presence and reach more customers in the Canadian healthcare sector
- In March 2024, Swift Medical secured a strategic co-investment from DIGITAL, Canada’s Global Innovation Cluster, to advance healthcare innovation in wound care. By leveraging AI, this collaboration aims to improve patient outcomes and treatment equity, helping Swift Medical lead the way in digital wound care management
